论文部分内容阅读
目的探讨液基薄层细胞学(LCT)联合第二代基因杂交捕获法(HC-Ⅱ)检测高危型人乳头瘤病毒(HR-HPV)在宫颈病变筛查中的临床价值。方法选取台州市中心医院门诊就诊患者1 500例,分为LCT组、HPV-DNA组和LCT联合HPV-DNA组,各500例。三组患者分别进行LCT检查、HPV-DNA检测和LCT联合HPV-DNA筛查,同时进行阴道镜下宫颈组织活检或宫颈管诊断性刮宫(ECC)检查。结果 LCT联合HPV-DNA组敏感性和阴性预测值均高于LCT组和HPV-DNA组,假阴性率最低。LCT联合HPV-DNA筛查阳性检出率均高于LCT组、HPV-DNA组(P均<0.05)。结论 HPV-DNA联合LCT进行宫颈病变筛查,可有效准确地提高宫颈癌和癌前病变的检出率。
Objective To investigate the clinical value of liquid-based TLCT combined with second generation hybridization capture (HC-Ⅱ) in the screening of high-risk human papillomavirus (HR-HPV) in cervical lesions screening. Methods A total of 1 500 outpatients were selected from Central Hospital of Taizhou City. They were divided into LCT group, HPV-DNA group and LCT combined with HPV-DNA group, 500 cases each. LCT, HPV-DNA and LCT combined with HPV-DNA screening were performed in the three groups. Cervical biopsy or endocervical diagnostic curettage (ECC) was performed simultaneously. Results The sensitivity and negative predictive value of LCT combined with HPV-DNA group were higher than LCT group and HPV-DNA group, the lowest false-negative rate. LCT combined HPV-DNA screening positive detection rate was higher than LCT group, HPV-DNA group (P all <0.05). Conclusion HPV-DNA combined with LCT for cervical lesions screening, can effectively and accurately improve the detection rate of cervical cancer and precancerous lesions.